整理 | GLP1减重宝典内容团队 美国疾病控制与预防中心（CDC）周四表示，去年超过四分之一的美国成年人糖尿病患者使用过针对GLP-1蛋白的注射类药物。 这些广受欢迎且疗效显著的GLP-1药物，包括礼来公司的Mounjaro和诺和诺德的Ozempic，已在美国获批用于治疗2型糖尿病。同时， 它们分别以Zepbound和Wegovy的名称销售用于减重，并正被测试用于其他疾病。 报告显示，使用比例最高的是50至64岁的糖尿病成年人，达到33.3%，反映出该年龄段疾病负担较重。18至34岁人群的使用率为 25.3%，65岁及以上人群为20.8%。 数据来自2024年进行的一项全国性年度调查，涵盖18岁及以上成年人。调查先进行面对面访谈，再通过电话回访。2024年首次向糖尿 病受访者询问是否使用礼来或诺和诺德的畅销药物，或其他GLP-1药物来控制血糖或减重。 GLP-1药物通过模拟调节血糖水平的激素作用，延缓消化，并延长饱腹感。礼来和诺和诺德因药物价格高昂而遭到批评，这类药物一 个月的标价约为1,000美元。 调查还显示，约31%的胰岛素使用者同时使用GLP-1药物；在口服降糖药患者中，这一比例约为28%，说明GL ...

Core Viewpoint - The article highlights the increasing usage of GLP-1 medications among diabetes patients in the U.S., indicating a significant trend in diabetes management and weight loss treatment [2][4]. Group 1: Usage Statistics - Over 25% of U.S. adults with diabetes used GLP-1 injection medications last year, with the highest usage among those aged 50 to 64 at 33.3% [2]. - The usage rate for the 18 to 34 age group is 25.3%, while for those aged 65 and above, it is 20.8% [2]. - Approximately 31% of insulin users also use GLP-1 medications, and about 28% of oral hypoglycemic drug users are incorporating GLP-1 into their treatment regimens [4]. Group 2: Demographic Insights - Among different ethnic groups, Hispanic diabetes adults have the highest GLP-1 usage rate at 31.3%, followed by non-Hispanic Black at 26.5% and non-Hispanic White at 26.2% [4]. - Non-Hispanic Asian individuals have the lowest usage rate at 12.1%, which may be attributed to differences in treatment accessibility or acceptance [4]. Group 3: Mechanism and Pricing - GLP-1 medications mimic the action of hormones that regulate blood sugar levels, delay digestion, and prolong feelings of fullness [4]. - The high cost of these medications, approximately $1,000 per month, has drawn criticism [4].